Issue
Parasite
Volume 21, 2014
Innovation for the Management of Echinococcosis. Invited editors: Dominique A. Vuitton, Laurence Millon, Bruno Gottstein and Patrick Giraudoux
Article Number 70
Number of page(s) 9
DOI https://doi.org/10.1051/parasite/2014073
Published online 22 December 2014
  1. Ali-Khan Z, Siboo R, Gomersall M, Faucher M. 1983. Cystolytic events and the possible role of germinal cells in metastasis in chronic alveolar hydatidosis. Annals of Tropical Medicine and Parasitology, 77, 497–512. [PubMed] [Google Scholar]
  2. Brehm K, Spiliotis M. 2008. Recent advances in the in vitro cultivation and genetic manipulation of Echinococcus multilocularis metacestodes and germinal cells. Experimental Parasitology, 119, 506–515. [CrossRef] [PubMed] [Google Scholar]
  3. Bresson-Hadni S, Laplante JJ, Lenys D, Rohmer P, Gottstein B, Jacquier P, Mercet P, Meyer JP, Miguet JP, Vuitton DA. 1994. Seroepidemiologic screening of Echinococcus multilocularis infection in a European area endemic for alveolar echinococcosis. American Journal of Tropical Medicine and Hygiene, 51, 837–846. [Google Scholar]
  4. Brunetti E, Kern P, Vuitton DA, Writing Panel for the WHO-IWGE. 2010. Expert consensus for the diagnosis and treatment of cystic and alveolar echinococcosis in humans. Acta Tropica, 114, 1–16. [CrossRef] [PubMed] [Google Scholar]
  5. Brunetti E, Troia G, Garlaschelli AL, Gulizia R, Filice C. 2004. Twenty years of percutaneous treatments for cystic echinococcosis: a preliminary assessment of their use and safety. Parassitologia, 46, 367–370. [PubMed] [Google Scholar]
  6. Cobo F, Yarnoz C, Sesma B, Fraile P, Aizcorbe M, Trujillo R, Diaz-de-Liaño A, Ciga MA. 1998. Albendazole plus praziquantel versus albendazole alone as a pre-operative treatment in intra-abdominal hydatisosis caused by Echinococcus granulosus. Tropical Medicine and International Health, 3, 462–466. [CrossRef] [Google Scholar]
  7. Eckert J, Deplazes P. 2004. Biological, epidemiological, and clinical aspects of echinococcosis, a zoonosis of increasing concern. Clinical Microbiology Reviews, 17, 107–135. [CrossRef] [PubMed] [Google Scholar]
  8. Eckert J, Thompson RC, Mehlhorn H. 1983. Proliferation and metastases formation of larval Echinococcus multilocularis. I. Animal model, macroscopical and histological findings. Zeitschrift für Parasitenkunde, 69, 737–748. [CrossRef] [Google Scholar]
  9. Fernández V, Chalar C, Martínez C, Musto H, Zaha A, Fernández C. 2000. Echinococcus granulosus: molecular cloning and phylogenetic analysis of an inducible glutathione S-transferase. Experimental Parasitology, 96, 190–194. [CrossRef] [PubMed] [Google Scholar]
  10. Gelmedin V, Caballero-Gamiz R, Brehm K. 2008. Characterization and inhibition of a p38-like mitogen-activated protein kinase (MAPK) from Echinococcus multilocularis: antiparasitic activities of p38 MAPK inhibitors. Biochemical Pharmacology, 76, 1068–1081. [CrossRef] [PubMed] [Google Scholar]
  11. Hemer S, Brehm K. 2012. In vitro efficacy of the anticancer drug imatinib on Echinococcus multilocularis larvae. International Journal of Antimicrobial Agents, 40, 458–462. [CrossRef] [PubMed] [Google Scholar]
  12. Hemphill A, Müller J. 2009. Alveolar and cystic echinococcosis: towards novel chemotherapeutical treatment options. Journal of Helminthology, 83, 99–111. [CrossRef] [PubMed] [Google Scholar]
  13. Hemphill A, Stadelmann B, Scholl S, Müller J, Spiliotis M, Müller N, Gottstein B, Siles-Lucas M. 2010. Echinococcus metacestodes as laboratory models for the screening of drugs against cestodes and trematodes. Parasitology, 137, 569–587. [CrossRef] [PubMed] [Google Scholar]
  14. Horton RJ. 1989. Chemotherapy of Echinococcus infection in man with albendazole. Transactions of the Royal Society of Tropical Medicine and Hygiene, 83, 97–102. [CrossRef] [PubMed] [Google Scholar]
  15. Hübner C, Wiehr S, Kocherscheidt L, Wehrl H, Pichler BJ, Schmid A, Kern P, Soboslay PT. 2010. Effects of in vitro exposure of Echinococcus multilocularis metacestodes to cytostatic drugs on in vivo growth and proliferation of the parasite. Parasitology Research, 107, 459–463. [CrossRef] [PubMed] [Google Scholar]
  16. Ingold K, Bigler P, Thormann W, Cavaliero T, Gottstein B, Hemphill A. 1999. Efficacies of albendazole sulfoxide and albendazole sulfone against in vitro-cultivated Echinococcus multilocularis metacestodes. Antimicrobial Agents and Chemotherapy, 43, 1052–1061. [PubMed] [Google Scholar]
  17. Jorgensen P, Van der Heiden M, Kern P, Schöneberg I, Krause G, Alpers K. 2008. Underreporting of human alveolar echinococcosis, Germany. Emerging Infectious Diseases, 14, 935–937. [CrossRef] [PubMed] [Google Scholar]
  18. Kaiser M, Wittlin S, Nehrbass-Stuedli A, Dong Y, Wang X, Hemphill A, Matile H, Brun R, Vennerstrom JL. 2007. Peroxide bond-dependent antiplasmodial specificity of artemisinin and OZ277 (RBx11160). Antimicrobial Agents and Chemotherapy, 51, 2991–2993. [CrossRef] [PubMed] [Google Scholar]
  19. Kern P. 2003. Echinococcus granulosus infection: clinical presentation, medical treatment and outcome. Langenbecks Archives of Surgery, 388, 413–420. [CrossRef] [Google Scholar]
  20. Kern P. 2006. Medical treatment of echinococcosis under the guidance of Good Clinical Practice (GCP/ICH). Parasitology International, 55(Suppl), S273–S282. [CrossRef] [PubMed] [Google Scholar]
  21. Kern P, Abboud P, Kern WV, Stich A, Bresson-Hadni S, Guerin B, Buttenschoen K, Gruener B, Reuter S, Hemphill A. 2008. Critical appraisal of nitazoxanide for the treatment of alveolar echinococcosis. American Journal for Tropical Medicine and Hygiene, 79, 119. [Google Scholar]
  22. Klinkert MQ, Heussler V. 2006. The use of anticancer drugs in antiparasitic chemotherapy. Mini Reviews in Medicinal Chemistry, 6, 131–143. [CrossRef] [PubMed] [Google Scholar]
  23. Küster T, Stadelmann B, Hermann C, Scholl S, Keiser J, Hemphill A. 2011. In vitro and in vivo efficacies of mefloquine-based treatment against alveolar echinococcosis. Antimicrobial Agents and Chemotherapy, 55, 713–721. [CrossRef] [PubMed] [Google Scholar]
  24. Küster T, Zumkehr B, Hermann C, Theurillat R, Thormann W, Gottstein B, Hemphill A. 2012. Voluntary ingestion of antiparasitic drugs emulsified in honey represents an alternative to gavage in mice. Journal of the American Association of Laboratory Animal Science, 51, 219–223. [Google Scholar]
  25. Küster T, Lense N, Barna F, Hemphill A, Kindermann MK, Heinicke JW, Vock CA. 2012. A new promising application for highly cytotoxic metal compounds: η6-areneruthenium(II) phosphite complexes for the treatment of alveolar echinococcosis. Journal of Medicinal Chemistry, 55, 4178–4188. [CrossRef] [PubMed] [Google Scholar]
  26. Küster T, Kriegel N, Boykin DW, Stephens CE, Hemphill A. 2013. In vitro and in vivo activities of dicationic diguanidino compounds against Echinococcus multilocularis metacestodes. Antimicrobial Agents and Chemotherapy, 57, 3829–3835. [CrossRef] [PubMed] [Google Scholar]
  27. Küster T, Hermann C, Hemphill A, Gottstein B, Spiliotis M. 2013. Subcutaneous infection model facilitates treatment assessment of secondary alveolar echinococcosis in mice. PLoS Neglected Tropical Diseases, 7, e2235. [CrossRef] [PubMed] [Google Scholar]
  28. Küster T, Kriegel N, Stadelmann B, Wang X, Dong Y, Vennerstrom JL, Keiser J, Hemphill A. 2014. Amino ozonides exhibit in vitro activity against Echinococcus multilocularis metacestodes. International Journal of Antimicrobial Agents, 43, 40–46. [CrossRef] [PubMed] [Google Scholar]
  29. Küster T, Stadelmann B, Aeschbacher D, Hemphill A. 2014. Activities of fenbendazole in comparison with albendazole against Echinococcus multilocularis metacestodes in vitro and in a murine infection model. International Journal of Antimicrobial Agents, 43, 335–342. [CrossRef] [PubMed] [Google Scholar]
  30. Liance M, Nemati F, Bories C, Couvreur P. 1993. Experience with doxorubicin-bound polyisohexyl-cyanoacrylate nanoparticles on murine alveolar echinococcosis of the liver. International Journal for Parasitology, 23, 427–429. [CrossRef] [PubMed] [Google Scholar]
  31. Liebau E, Müller V, Lucius R, Walter RD, Henkle-Dührsen K. 1996. Molecular cloning, expression and characterization of a recombinant glutathione S-transferase from Echinococcus multilocularis. Molecular and Biochemical Parasitology, 77, 49–56. [CrossRef] [PubMed] [Google Scholar]
  32. Mathis A, Wild P, Boettger EC, Kapel CM, Deplazes P. 2005. Mitochondrial ribosome as the target for the macrolide antibiotic clarithromycin in the helminth Echinococcus multilocularis. Antimicrobial Agents and Chemotherapy, 49, 3251–3255. [CrossRef] [PubMed] [Google Scholar]
  33. Mehlhorn H, Eckert J, Thompson RC. 1983. Proliferation and metastases formation of larval Echinococcus multilocularis. II. Ultrastructural investigations. Zeitschrift für Parasitenkunde, 69, 749–763. [CrossRef] [Google Scholar]
  34. Messina MJ. 1999. Legumes and soybeans: overview of their nutritional profiles and health effects. American Journal of Clinical Nutrition, 70, 439S–450S. [Google Scholar]
  35. Müller J, Sidler D, Nachbur U, Wastling J, Brunner T, Hemphill A. 2008. Thiazolides inhibit growth and induce glutathione-S-transferase Pi (GSTP1)-dependent cell death in human colon cancer cells. International Journal of Cancer, 123, 1797–1806. [CrossRef] [Google Scholar]
  36. Naguleswaran A, Spicher M, Vonlaufen N, Ortega-Mora LM, Torgerson P, Gottstein B, Hemphill A. 2006. In vitro metacestodicidal activities of genistein and other isoflavones against Echinococcus multilocularis and Echinococcus granulosus. Antimicrobial Agents and Chemotherapy, 50, 3770–3778. [CrossRef] [PubMed] [Google Scholar]
  37. Nakao M, McManus DP, Schantz PM, Craig PS, Ito A. 2007. A molecular phylogeny of the genus Echinococcus inferred from complete mitochondrial genomes. Parasitology, 134, 713–722. [CrossRef] [PubMed] [Google Scholar]
  38. Pérez-Molina JA, Díaz-Menéndez M, Gallego JI, Norman F, Monge-Maillo B, Ayala AP, López-Vélez R. 2011. Evaluation of nitazoxanide for the treatment of disseminated cystic echinococcosis: report of five cases and literature review. American Journal for Tropical Medicine and Hygiene, 84, 351–356. [CrossRef] [Google Scholar]
  39. Pike AC, Brzozowski AM, Hubbard RE, Bonn T, Thorsell AG, Engström O, Ljunggren J, Gustafsson JA, Carlquist M. 1999. Structure of the ligand-binding domain of oestrogen receptor beta in the presence of a partial agonist and a full antagonist. European Molecular Biology Organization Journal, 18, 4608–4618. [CrossRef] [Google Scholar]
  40. Reuter S, Jensen B, Buttenschoen K, Kratzer W, Kern P. 2000. Benzimidazoles in the treatment of alveolar echinococcosis: a comparative study and review of the literature. Journal of Antimicrobial Chemotherapy, 46, 451–456. [CrossRef] [Google Scholar]
  41. Reuter S, Buck A, Grebe O, Nüssle-Kügele K, Kern P, Manfras BJ. 2003. Salvage treatment with amphotericin B in progressive human alveolar echinococcosis. Antimicrobial Agents and Chemotherapy, 47, 3586–3591. [CrossRef] [PubMed] [Google Scholar]
  42. Reuter S, Merkle M, Brehm K, Kern P, Manfras B. 2003. Effect of amphotericin B on larval growth of Echinococcus multilocularis. Antimicrobial Agents and Chemotherapy, 47, 620–625. [CrossRef] [PubMed] [Google Scholar]
  43. Reuter S, Buck A, Manfras B, Kratzer W, Seitz HM, Darge K, Reske SN, Kern P. 2004. Structured treatment interruption in patients with alveolar echinococcosis. Hepatology, 39, 509–517. [CrossRef] [PubMed] [Google Scholar]
  44. Reuter S, Manfras B, Merkle M, Härter G, Kern P. 2006. In vitro activities of itraconazole, methiazole, and nitazoxanide versus Echinococcus multilocularis larvae. Antimicrobial Agents and Chemotherapy, 50, 2966–2970. [CrossRef] [PubMed] [Google Scholar]
  45. Richter D, Richter J, Grüner B, Kranz K, Franz J, Kern P. 2013. In vitro efficacy of triclabendazole and clorsulon against the larval stage of Echinococcus multilocularis. Parasitology Research, 112, 1655–1660. [CrossRef] [PubMed] [Google Scholar]
  46. Sander P, Prammananan T, Meier A, Frischkorn K, Böttger EC. 1997. The role of ribosomal RNAs in macrolide resistance. Molecular Microbiology, 26, 469–480. [CrossRef] [PubMed] [Google Scholar]
  47. Schubert A, Koziol U, Cailliau K, Vanderstraete M, Dissous C, Brehm K. 2014. Targeting Echinococcus multilocularis stem cells by inhibition of the polo-like kinase EmPlk1. PLoS Neglected Tropical Diseases, 8, e2870. [CrossRef] [PubMed] [Google Scholar]
  48. Siles-Lucas M, Hemphill A. 2002. Cestode parasites: application of in vivo and in vitro models for studies on the host-parasite relationship. Advances in Parasitology, 51, 133–230. [CrossRef] [PubMed] [Google Scholar]
  49. Spicher M, Roethlisberger C, Lany C, Stadelmann B, Keiser J, Ortega-Mora LM, Gottstein B, Hemphill A. 2008. In vitro and in vivo treatments of Echinococcus protoscoleces and metacestodes with artemisinin and artemisinin derivatives. Antimicrobial Agents and Chemotherapy, 52, 3447–3450. [CrossRef] [PubMed] [Google Scholar]
  50. Spicher M, Naguleswaran A, Ortega-Mora LM, Müller J, Gottstein B, Hemphill A. 2008. In vitro and in vivo effects of 2-methoxyestradiol, either alone or combined with albendazole, against Echinococcus metacestodes. Experimental Parasitology, 119, 475–482. [CrossRef] [PubMed] [Google Scholar]
  51. Spiliotis M, Konrad C, Gelmedin V, Tappe D, Brückner S, Mösch HU, Brehm K. 2006. Characterisation of EmMPK1, an ERK-like MAP kinase from Echinococcus multilocularis which is activated in response to human epidermal growth factor. International Journal for Parasitology, 36, 1097–1112. [CrossRef] [PubMed] [Google Scholar]
  52. Spiliotis M, Lechner S, Tappe D, Scheller C, Krohne G, Brehm K. 2008. Transient transfection of Echinococcus multilocularis primary cells and complete in vitro regeneration of metacestode vesicles. International Journal for Parasitology, 38, 1025–1039. [CrossRef] [PubMed] [Google Scholar]
  53. Spiliotis M, Brehm K. 2009. Axenic in vitro cultivation of Echinococcus multilocularis metacestode vesicles and the generation of primary cell cultures. Methods in Molecular Biology, 470, 245–262. [CrossRef] [Google Scholar]
  54. Spiliotis M, Mizukami C, Oku Y, Kiss F, Brehm K, Gottstein B. 2010. Echinococcus multilocularis primary cells: improved isolation, small-scale cultivation and RNA interference. Molecular Biochemical Parasitology, 174, 83–87. [CrossRef] [PubMed] [Google Scholar]
  55. Stadelmann B, Scholl S, Müller J, Hemphill A. 2010. Application of an in vitro drug screening assay based on the release of phosphoglucose isomerase to determine the structure-activity relationship of thiazolides against Echinococcus multilocularis metacestodes. Journal of Antimicrobial Chemotherapy, 65, 512–519. [CrossRef] [Google Scholar]
  56. Stadelmann B, Küster T, Scholl S, Barna F, Kropf C, Keiser J, Boykin DW, Stephens CE, Hemphill A. 2011. In vitro efficacy of dicationic compounds and mefloquine enantiomers against Echinococcus multilocularis metacestodes. Antimicrobial Agents and Chemotherapy, 55, 4866–4872. [CrossRef] [PubMed] [Google Scholar]
  57. Stadelmann B, Aeschbacher D, Huber C, Spilitotis M, Müller J, Hemphill A. 2014. Profound activity of the anti-cancer drug bortezomib against Echinococcus multilocularis metacestodes identifies the proteasome as a novel drug target for cestodes. PLoS Neglected Tropical Diseases, 8, e3352. [CrossRef] [PubMed] [Google Scholar]
  58. Stettler M, Fink R, Walker M, Gottstein B, Geary TG, Rossignol JF, Hemphill A. 2003. In vitro parasiticidal effect of Nitazoxanide against Echinococcus multilocularis metacestodes. Antimicrobial Agents and Chemotherapy, 47, 467–474. [CrossRef] [PubMed] [Google Scholar]
  59. Stettler M, Rossignol JF, Fink R, Walker M, Gottstein B, Merli M, Theurillat R, Thormann W, Dricot E, Segers R, Hemphill A. 2004. Secondary and primary murine alveolar echinococcosis: combined albendazole/nitazoxanide chemotherapy exhibits profound anti-parasitic activity. International Journal for Parasitology, 34, 615–624. [CrossRef] [PubMed] [Google Scholar]
  60. Stumpe KD, Renner-Schneiter EC, Kuenzle AK, Grimm F, Kadry Z, Clavien PA, Deplazes P, von Schulthess GK, Muellhaupt B, Ammann RW, Renner EL. 2007. F-18-fluorodeoxyglucose (FDG) positron-emission tomography of Echinococcus multilocularis liver lesions: prospective evaluation of its value for diagnosis and follow-up during benzimidazole therapy. Infection, 35, 11–18. [CrossRef] [PubMed] [Google Scholar]
  61. Tappe D, Müller A, Frosch M, Stich A. 2009. Limitations of amphotericin B and nitazoxanide in the treatment of alveolar echinococcosis. Annales of Tropical Medicine and Parasitology, 103, 177–181. [CrossRef] [Google Scholar]
  62. Torgerson PR, de Silva NR, Fèvre EM, Kasuga F, Rokni MB, Zhou XN, Sripa B, Gargouri N, Willingham AL, Stein C. 2014. The global burden of foodborne parasitic diseases: an update. Trends in Parasitology, 30, 20–26. [CrossRef] [PubMed] [Google Scholar]
  63. Torgerson PR. 2003. Economic effects of echinococcosis. Acta Tropica, 85, 113–118. [CrossRef] [PubMed] [Google Scholar]
  64. Tsai IJ, Zarowiecki M, Holroyd N, Garciarrubio A, Sanchez-Flores A, Brooks KL, Tracey A, Bobes RJ, Fragoso G, Sciutto E, Aslett M, Beasley H, Bennett HM, Cai J, Camicia F, Clark R, Cucher M, De Silva N, Day TA, Deplazes P, Estrada K, Fernández C, Holland PW, Hou J, Hu S, Huckvale T, Hung SS, Kamenetzky L, Keane JA, Kiss F, Koziol U, Lambert O, Liu K, Luo X, Luo Y, Macchiaroli N, Nichol S, Paps J, Parkinson J, Pouchkina-Stantcheva N, Riddiford N, Rosenzvit M, Salinas G, Wasmuth JD, Zamanian M, Zheng Y, Cai X, Taenia solium Genome Consortium, Soberón X, Olson PD, Laclette JP, Brehm K, Berriman M. 2013. The genomes of four tapeworm species reveal adaptations to parasitism. Nature, 496, 57–63. [CrossRef] [PubMed] [Google Scholar]
  65. Urrea-París MA, Casado N, Moreno MJ, Rodriguez-Caabeiro F. 2001. Chemoprophylactic praziquantel treatment in experimental hydatidosis. Parasitology Research, 87, 510–512. [CrossRef] [PubMed] [Google Scholar]
  66. Urrea-París MA, Moreno MJ, Casado N, Rodriguez-Caabeiro F. 1999. Echinococcus granulosus: praziquantel treatment against the metacestode stage. Parasitology Research, 85, 999–1006. [CrossRef] [PubMed] [Google Scholar]
  67. Walker M, Rossignol JF, Torgerson P, Hemphill A. 2004. In vitro effects of nitazoxanide on Echinococcus granulosus protoscoleces and metacestodes. Journal of Antimicrobial Chemotherapy, 54, 609–616. [CrossRef] [Google Scholar]
  68. Winning A, Braslins P, McCarthy JS. 2009. Case report: nitazoxanide for treatment of refractory bony hydatid disease. American Journal for Tropical Medicine and Hygiene, 79(80), 176–178. [Google Scholar]
  69. Zheng H, Zhang W, Zhang L, Zhang Z, Li J, Lu G, Zhu Y, Wang Y, Huang Y, Liu J, Kang H, Chen J, Wang L, Chen A, Yu S, Gao Z, Jin L, Gu W, Wang Z, Zhao L, Shi B, Wen H, Lin R, Jones MK, Brejova B, Vinar T, Zhao G, McManus DP, Chen Z, Zhou Y, Wang S. 2013. The genome of the hydatid tapeworm Echinococcus granulosus. Nature Genetics, 45, 1168–1175. [CrossRef] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.